X0306 4 2017-01-30 0 0001269021 PORTOLA PHARMACEUTICALS INC PTLA 0001574589 Curnutte John T C/O PORTOLA PHARMACEUTICALS, INC. 270 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Executive Vice President Common Stock 2017-01-30 4 A 0 12500 0.00 A 12500 D Stock Option (Right to Buy) 25.54 2017-01-30 4 A 0 50000 0.00 A 2027-01-30 Common Stock 50000 50000 D Performance Stock Unit 2017-01-30 4 A 0 12500 0.00 A 2027-01-30 Common Stock 12500 12500 D Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2017, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. The option shares shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 1, 2017, subject to the Reporting Person's Continuous Service as of each such date. Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Issuer's Common Stock. The PSUs vest as follows: (i) 50% of the PSUs will become vested upon the date of the Compensation Committee's certification of regulatory approval of Andexanet alfa in either the United States or European Union (the "Certification Date") in 2017, with the remaining 50% vesting on the first anniversary of the Certification Date, or (ii) 37.5% of the PSUs will become vested upon the Certification Date in 2018, with the remaining 37.5% vesting on the first anniversary of the Certification Date. If the Certification Date does not occur prior to the end of 2018, the PSUs shall not vest. /s/ Mike Ouimettte, as-attorney-in-fact 2017-02-01